MedTrace Logo

Pegfilgrastim Versus Filgrastim After High-dose Chemotherapy

NCT00410696 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 80

Last updated 2013-07-01

No results posted yet for this study

Summary

The primary objective of the study is to evaluate the efficacy and the safety of pegfilgrastim versus filgrastim, administered after high-dose chemotherapy and peripheral stem cell reinfusion.

Conditions

  • Hematological Neoplasms
  • Tumors

Interventions

DRUG

Filgrastim

5 mcg/kg/day sc from day +1 after transplantation to hemopoietic reconstitution

DRUG

Pegfilgrastim

6 mg/day sc at day +1

Sponsors & Collaborators

  • Armando Santoro, MD

    lead OTHER

Principal Investigators

  • Armando Santoro, MD · Istituto Clinico Humanitas

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-09-30
Primary Completion
2008-11-30
Completion
2008-11-30

Countries

  • Italy

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00410696 on ClinicalTrials.gov